Inflammatory Myofibroblastic Tumor Showing Durable Remission after Anthracycline-Containing Cytotoxic Chemotherapy: Report of a Case.
- Author:
Dal Yong KIM
1
;
Han Seung PARK
;
Sun Mok KIM
;
Ji Hyun PARK
;
Yong Sang HONG
;
Jae Lyun LEE
;
Cheolwon SUH
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. csuh@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Inflammatory myofibroblastic tumor;
Anthracycline-containing chemotherapy
- MeSH:
Abdominal Pain;
Adrenal Cortex Hormones;
Benzeneacetamides;
Biopsy, Large-Core Needle;
Disease Progression;
Humans;
Liver;
Mesenteric Artery, Superior;
Mesentery;
Middle Aged;
Myofibroblasts;
Neoplasm Metastasis;
Piperidones;
Rare Diseases;
Weight Loss
- From:Korean Journal of Medicine
2012;82(6):749-753
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
An inflammatory myofibroblastic tumor (IMT) is a rare disease entity, and the clinical characteristics range from indolent to aggressive forms. No established management for patients with unresectable or aggressive IMT is available. We report on a 62-year-old patient with aggressive IMT who achieved a durable partial response lasting 12 months after anthracycline-containing cytotoxic chemotherapy without corticosteroids. The patient was admitted for an evaluation of progressive weight loss and lower abdominal pain lasting for 2 weeks. Abdominopelvic computed tomography revealed a 10 cm sized heterogeneous mass in the mesentery that encased the superior mesenteric artery and a liver metastasis. The diagnosis of IMT was confirmed by percutaneous core needle biopsy of the mesenteric mass. Systemic chemotherapy was performed after confirming disease progression during a 1 month observation period. A partial response was obtained after two cycles of chemotherapy. Anthracycline-containing cytotoxic chemotherapy could be a treatment option for patients with aggressive IMT.
